ToGA, a large international randomized phase III study, investigated the efficacy and safety of adding trastuzumab to combination chemotherapy of a fluoropyrimidine (capecitabine or 5-FU) plus cisplatin for the upfront treatment of HER2-positive advanced gastric cancer patients [9]. Here, ERBB2 is linked to gastric cancer.